Effect of imatinib mesylate on chronic myelogenous leukemia hematopoietic progenitor cells (Q35752831)

10 August 2017

1 reference

title

Effect of imatinib mesylate on chronic myelogenous leukemia hematopoietic progenitor cells (English)

1 reference

10 August 2017

1 reference

Melissa S Holtz

1

1 reference

PubMed ID

15101707

10 August 2017

Ravi Bhatia

series ordinal

2

1 reference

10 August 2017

1 February 2004

1 reference

10 August 2017

1 reference

10 August 2017

45

1 reference

10 August 2017

2

1 reference

10 August 2017

237-245

1 reference

Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein

10 August 2017

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000151905

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000151905

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000151905

Progenitor cells from patients with advanced phase chronic myeloid leukaemia respond to STI571 in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000151905

Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000151905

Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000151905

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000151905

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000151905

BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000151905

Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000151905

BCR/ABL amplification in chronic myelocytic leukemia blast crisis following imatinib mesylate administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000151905

Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000151905

In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000151905

In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000151905

Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000151905

Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000151905

Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000151905

Favorable therapeutic index of a p210(BCR-ABL)-specific tyrosine kinase inhibitor; activity on lineage-committed and primitive chronic myelogenous leukemia progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000151905

Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000151905

10.1080/1042819031000151905

21 January 2018

Identifiers

DOI

1 reference

10 August 2017

1 reference

PubMed ID

15101707